Does the media favor TXG or ALMR?

In the previous week, 10x Genomics had 9 more articles in the media than Alamar Biosciences. MarketBeat recorded 11 mentions for 10x Genomics and 2 mentions for Alamar Biosciences. 10x Genomics' average media sentiment score of 0.67 beat Alamar Biosciences' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAI or ALMR?

In the previous week, Caris Life Sciences had 5 more articles in the media than Alamar Biosciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 2 mentions for Alamar Biosciences. Caris Life Sciences' average media sentiment score of 1.02 beat Alamar Biosciences' score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate STVN or ALMR?

Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 4.02%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Alamar Biosciences 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Does the media favor STVN or ALMR?

In the previous week, Stevanato Group had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 6 mentions for Stevanato Group and 2 mentions for Alamar Biosciences. Stevanato Group's average media sentiment score of 1.14 beat Alamar Biosciences' score of 0.00 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SHC or ALMR?

In the previous week, Sotera Health had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Sotera Health and 2 mentions for Alamar Biosciences. Sotera Health's average media sentiment score of 1.38 beat Alamar Biosciences' score of 0.00 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALMR or ADPT?

In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 2 mentions for Alamar Biosciences. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Alamar Biosciences' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alamar Biosciences (ALMR) Competitors

$30.57 +0.08 (+0.26%)

As of 04:00 PM Eastern

Compare

ALMR vs. TXG, CAI, STVN, SHC, and ADPT

Should you buy Alamar Biosciences stock or one of its competitors? Alamar Biosciences's main competitors and comparable companies include 10x Genomics (TXG), Caris Life Sciences (CAI), Stevanato Group (STVN), Sotera Health (SHC), and Adaptive Biotechnologies (ADPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Alamar Biosciences compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

10x Genomics presently has a consensus price target of $40.57, suggesting a potential downside of 35.83%. Alamar Biosciences has a consensus price target of $31.80, suggesting a potential upside of 4.02%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, 10x Genomics had 9 more articles in the media than Alamar Biosciences. MarketBeat recorded 11 mentions for 10x Genomics and 2 mentions for Alamar Biosciences. 10x Genomics' average media sentiment score of 0.67 beat Alamar Biosciences' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to 10x Genomics' net margin of -12.18%. Alamar Biosciences' return on equity of 0.00% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Alamar Biosciences	N/A	N/A	N/A

Alamar Biosciences has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	12.81	-$43.54M	-$0.59	N/A
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A

Summary

Alamar Biosciences beats 10x Genomics on 8 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Caris Life Sciences has a net margin of 10.62% compared to Alamar Biosciences' net margin of 0.00%. Caris Life Sciences' return on equity of 18.77% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Alamar Biosciences	N/A	N/A	N/A

Caris Life Sciences currently has a consensus price target of $26.33, suggesting a potential upside of 4.00%. Alamar Biosciences has a consensus price target of $31.80, suggesting a potential upside of 4.02%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has lower revenue, but higher earnings than Caris Life Sciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	8.81	-$68.09M	$0.36	70.33
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A

In the previous week, Caris Life Sciences had 5 more articles in the media than Alamar Biosciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 2 mentions for Alamar Biosciences. Caris Life Sciences' average media sentiment score of 1.02 beat Alamar Biosciences' score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Caris Life Sciences beats Alamar Biosciences on 10 of the 13 factors compared between the two stocks.

How does Alamar Biosciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Stevanato Group had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 6 mentions for Stevanato Group and 2 mentions for Alamar Biosciences. Stevanato Group's average media sentiment score of 1.14 beat Alamar Biosciences' score of 0.00 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 4.02%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Stevanato Group has a net margin of 10.99% compared to Alamar Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.43% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Alamar Biosciences	N/A	N/A	N/A

Stevanato Group has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.23B	5.08	€158.21M	€0.56	36.70
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A

Summary

Stevanato Group beats Alamar Biosciences on 11 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Sotera Health currently has a consensus target price of $21.50, suggesting a potential upside of 12.98%. Alamar Biosciences has a consensus target price of $31.80, suggesting a potential upside of 4.02%. Given Sotera Health's stronger consensus rating and higher probable upside, research analysts clearly believe Sotera Health is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Sotera Health had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Sotera Health and 2 mentions for Alamar Biosciences. Sotera Health's average media sentiment score of 1.38 beat Alamar Biosciences' score of 0.00 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sotera Health has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.67	$77.94M	$0.57	33.39
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A

Sotera Health has a net margin of 13.44% compared to Alamar Biosciences' net margin of 0.00%. Sotera Health's return on equity of 40.12% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Alamar Biosciences	N/A	N/A	N/A

Summary

Sotera Health beats Alamar Biosciences on 14 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Alamar Biosciences (NASDAQ:ALMR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Alamar Biosciences presently has a consensus price target of $31.80, suggesting a potential upside of 4.02%. Adaptive Biotechnologies has a consensus price target of $24.42, suggesting a potential downside of 0.62%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 2 mentions for Alamar Biosciences. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Alamar Biosciences' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alamar Biosciences has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A
Adaptive Biotechnologies	$276.98M	14.16	-$59.50M	-$0.41	N/A

Alamar Biosciences has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -20.73%. Alamar Biosciences' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Summary

Adaptive Biotechnologies beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

Get Alamar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMR vs. The Competition

Export

Metric	Alamar Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.12B	$10.02B	$7.24B	$12.90B
Dividend Yield	N/A	1.47%	2.53%	8.56%
P/E Ratio	-15.60	64.84	273.57	25.42
Price / Sales	28.58	112.60	675.05	123.41
Price / Cash	N/A	26.42	76.98	52.08
Price / Book	6.78	36.39	12.91	6.15
Net Income	-$29.82M	$56.67B	$3.47B	$349.01M
7 Day Performance	-7.36%	-2.72%	-0.46%	-1.48%
1 Month Performance	12.93%	5.39%	6.40%	2.46%
1 Year Performance	N/A	26.77%	24.88%	15.76%

Alamar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMR Alamar Biosciences	1.6242 of 5 stars	$30.57 +0.3%	$31.80 +4.0%	N/A	$2.12B	$74.21M	N/A	222
TXG 10x Genomics	1.382 of 5 stars	$61.54 -5.1%	$38.31 -37.8%	+361.1%	$8.02B	$642.82M	N/A	1,240	Analyst Forecast
CAI Caris Life Sciences	2.6237 of 5 stars	$25.63 -2.8%	$26.33 +2.7%	N/A	$7.24B	$812.03M	71.19	1,846	Positive News
STVN Stevanato Group	3.0267 of 5 stars	€21.10 -5.4%	N/A	-8.6%	€6.37B	€1.34B	37.68	6,010	Positive News
SHC Sotera Health	4.062 of 5 stars	$19.27 -1.1%	$21.50 +11.6%	+17.3%	$5.50B	$1.16B	33.81	3,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alamar Biosciences (ALMR) Competitors

ALMR vs. TXG, CAI, STVN, SHC, and ADPT

How does Alamar Biosciences compare to 10x Genomics?

Summary

How does Alamar Biosciences compare to Caris Life Sciences?

Summary

How does Alamar Biosciences compare to Stevanato Group?

Summary

How does Alamar Biosciences compare to Sotera Health?

Summary

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alamar Biosciences (ALMR) Competitors

ALMR vs. TXG, CAI, STVN, SHC, and ADPT

How does Alamar Biosciences compare to 10x Genomics?

Do analysts recommend TXG or ALMR?

Do insiders and institutionals have more ownership in TXG or ALMR?

Does the media favor TXG or ALMR?

Is TXG or ALMR more profitable?

Which has better earnings and valuation, TXG or ALMR?

Summary

How does Alamar Biosciences compare to Caris Life Sciences?

Is CAI or ALMR more profitable?

Do analysts rate CAI or ALMR?

Which has preferable earnings and valuation, CAI or ALMR?

Does the media prefer CAI or ALMR?

Summary

How does Alamar Biosciences compare to Stevanato Group?

Does the media favor STVN or ALMR?

Do analysts rate STVN or ALMR?

Is STVN or ALMR more profitable?

Which has stronger valuation & earnings, STVN or ALMR?

Summary

How does Alamar Biosciences compare to Sotera Health?

Do analysts recommend SHC or ALMR?

Does the media prefer SHC or ALMR?

Do institutionals and insiders have more ownership in SHC or ALMR?

Which has preferable valuation and earnings, SHC or ALMR?

Is SHC or ALMR more profitable?

Summary

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Do analysts recommend ALMR or ADPT?

Do insiders & institutionals have more ownership in ALMR or ADPT?

Does the media refer more to ALMR or ADPT?

Which has better valuation & earnings, ALMR or ADPT?

Is ALMR or ADPT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools